Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-10

Study Completion Date

2028-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is to evaluate the efficacy and safety of Amimestrocel (human umbilical cord mesenchymal stromal cells) in the treatment of AKI patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury

NCT04194671

Acute Kidney Injury Mesenchymal Stem Cells

UNKNOWN PHASE1/PHASE2

Mesenchymal Stem Cells for Chronic Kidney Diseases

NCT07240987

Kidney Disease, Chronic Diabetic Kidney Disease (DKD) Hypertensive Nephropathy

NOT_YET_RECRUITING PHASE1/PHASE2

Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy

NCT00659620

Kidney Transplant Chronic Allograft Nephropathy

UNKNOWN PHASE1/PHASE2

Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy

NCT02478242

Acute Kidney Injury

COMPLETED PHASE4

Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 )

NCT05512988

Chronic Kidney Diseases

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amimestrocel

In experimental group,patients receive standard treatment and Amimestrocel is administered via Intravenous infusion on day 1, 4, 8,15.

Group Type EXPERIMENTAL

Amimestrocel

Intervention Type DRUG

Amimestrocel will be administered at a target dose of 1×10E6 MSCs/kg body weight on day 1, 4, 8, 15.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amimestrocel

Amimestrocel will be administered at a target dose of 1×10E6 MSCs/kg body weight on day 1, 4, 8, 15.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged between 18 and 75 years old; gender is not restricted.
2. According to the 2023 KDIGO diagnostic criteria for acute kidney injury (AKI), including those that occur during the course of the disease in various patients with chronic kidney disease (CKD), AKI can be diagnosed if any of the following conditions is met:

① The serum creatinine level increases by ≥ 26.5 μmol/L within 48 hours;

② The serum creatinine level increases by more than 1.5 times or higher than the baseline value within 7 days;

③ The urine output decreases (\< 0.5 mL/kg/h) and persists for more than 6 hours; The baseline value of serum creatinine: The lowest creatinine value obtained in the outpatient department or ward within 3 months, and the longest time limit is the creatinine value within 1 year. If there is no such value, the serum creatinine can be estimated using the MDRD equation under the assumption that the baseline eGFR is 75 ml/min/1.73m².
3. .Ability to give informed consent.

Exclusion Criteria

1. Post-renal AKI.
2. Acute kidney injury caused by glomerular diseases such as rapidly progressive glomerulonephritis, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, anti-glomerular basement membrane antibody-mediated nephritis, vasculitis, cryoglobulinemia, thrombotic microangiopathy, etc.
3. Hemodynamic instability.
4. Severe cardiovascular diseases.
5. Severe pulmonary dysfunction.
6. A history of intracerebral hemorrhage or cerebral infarction within the past six months.
7. Subjects with abnormal laboratory indicators: AST or ALT \> 5 × upper limit of normal value (ULN); total bilirubin \> 3 × ULN; white blood cell count \< 2000/μL (2 × 10⁹/L), hemoglobin \< 6 g/dL (60 g/L), neutrophils \< 1000/μL (1 × 10⁹/L), platelets \< 50000/μL (50 × 10⁹/L).
8. Uncontrollable infection.
9. Patients with active hepatitis B or hepatitis C virus infection, active tuberculosis, severe immunodeficiency diseases, human immunodeficiency virus (HIV) infection, etc.
10. Received systemic immunosuppressants or glucocorticoid treatment for more than one week within 30 days before enrollment.
11. Have received hemodialysis or peritoneal dialysis treatment.
12. Have a history of hematopoietic stem cell transplantation or solid organ transplantation.
13. Patients with a history of malignant tumor within the past 5 years.
14. Life expectancy is less than 1 month.
15. Those with a known history of severe allergy to component blood or blood products, or those with a history of allergy to heterologous proteins.
16. Lactating women, or female patients who have a pregnancy plan or an egg donation plan from the start of the study to the follow-up period, and male patients (or their partners) who have a fertility plan or a sperm donation plan from the start of the study to the follow-up period and are unwilling to take contraceptive measures.
17. Patients who participated in other interventional clinical trials within 1 month before enrollment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chen Xiangmei

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.